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Study	 Characteristics	 Treatment	Details	 Mean	Change	from	Baseline		
Gassmueller	et	al.	2008
10
	
N:	102	
Age:	38	
Severity:	III	to	Va	
Duration:	16	wks	
Vehicle	(2x	day)	 0.7	mm/cm
2
	
Fulvestrant	(70	mg/mL,	42	mg/day)	 0.84	mm/cm
2
	
Minoxidil		(20	mg/mL,	12	mg/day)	 2.9	mm/cm
2
*,^
	
NCT01325337
22	 N:	307	
Duration:	24	wks	
Bimatoprost	Formulation	C	(1x	day)	 0.12	mm/cm
2
	
Vehicle	(1x	day)	 0.13	mm/cm
2
	
Bimatoprost	Formulation	B	(1x	day)	 0.25	mm/cm
2
	
Bimatoprost	Formulation	A	(1x	day)	 0.76	mm/cm
2
	
Minoxidil	(5%,	1x	day)		 1.29	mm/cm
2
	
NCT01904721
23	 N:	244	
Duration:	7-24	wks	
Vehicle	(2x	day)	 0.05	mm/cm
2
	
Bimatoprost	Solution	2	(2x	day)	 0.67	mm/cm
2
	
Bimatoprost	Solution	1	(2x	day)	 0.92	mm/cm
2
	
*p<0.05	as	compared	to	placebo	/	vehicle;	^p<0.05	as	compared	to	investigated	off-label	topical	therapy;	Age	(years):	Mean;	Severity:	Based	on	Hamilton-Norwood	Scale	
and	eligibility	criteria;	Wks:	weeks;	Bimatoprost	A,	B,	C,	solution	1	and	solution	2:	Details	on	these	treatment	groups	(e.g.,	percentage	of	bimatoprost)	not	yet	released	on	
clinicaltrials.gov		
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Figure	1.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Records	identified	through	databases 
(N	=	1004) 
Records	after	title	and	abstract	exclusion 
(N	=	113) 
Records	after	full	text	exclusion 
(N	=	42) 
Records	included	in	review 
(N	=	16) 
Title	and	abstract	
exclusion 
(N	=	891) 
Full	text	exclusion 
(N	=	71) 
Exclusion	during	
data	extraction 
(N	=	26) 
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Figure	2	
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